Clinical Trials Logo

Adenocarcinoma of the Prostate clinical trials

View clinical trials related to Adenocarcinoma of the Prostate.

Filter by:

NCT ID: NCT01126879 Terminated - Clinical trials for Adenocarcinoma of the Prostate

Genistein in Treating Patients With Prostate Cancer

Start date: February 3, 2011
Phase: Phase 2
Study type: Interventional

RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This randomized phase II trial is studying how well genistein works in treating patients with prostate cancer.

NCT ID: NCT01093183 Terminated - Clinical trials for Adenocarcinoma of the Prostate

Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer

Start date: March 4, 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of lenalidomide when given together with cyclophosphamide and to see how well they work in treating patients with previously treated hormone-refractory prostate cancer. Lenalidomide may stop the growth of prostate cancer by blocking blood flow to the tumor. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving lenalidomide together with cyclophosphamide may kill more tumor cells.

NCT ID: NCT00879619 Terminated - Prostate Cancer Clinical Trials

Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients

Start date: July 2009
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving docetaxel and prednisone together with sunitinib malate may kill more tumor cells. PURPOSE: This pilot phase I/II trial studies the side effects and best way to give docetaxel and prednisone together with sunitinib malate and to see how well it works in treating patients with prostate cancer that progressed after hormone therapy.

NCT ID: NCT00527124 Terminated - Clinical trials for Adenocarcinoma of the Prostate

Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Start date: November 2007
Phase: Phase 2
Study type: Interventional

This randomized phase II trial is studying how well giving docetaxel and prednisone together with or without cediranib works in treating patients with metastatic prostate cancer that did not respond to hormone therapy. Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cediranib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving docetaxel together with prednisone, with or without cediranib, may kill more tumor cells.

NCT ID: NCT00512668 Terminated - Clinical trials for Adenocarcinoma of the Prostate

Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer

Start date: September 2007
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of temsirolimus when given together with hormone therapy in treating patients with relapsed prostate cancer. Androgens can cause the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by lowering the amount of androgens the body makes. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving hormone therapy together with temsirolimus may kill more tumor cells

NCT ID: NCT00058214 Terminated - Clinical trials for Adenocarcinoma of the Prostate

Perifosine in Treating Patients With Recurrent Prostate Cancer

Start date: March 2003
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of perifosine in treating patients who have recurrent prostate cancer. Drugs used in chemotherapy such as perifosine use different ways to stop tumor cells from dividing so they stop growing or die

NCT ID: NCT00019695 Terminated - Bone Metastases Clinical Trials

Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer

Start date: March 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Ketoconazole may suppress the production of hormones and may interfere in the growth of prostate cancer cells. Alendronate sodium may be effective in preventing bone metastases and bone pain associated with prostate cancer. It is not known if ketoconazole is more effective with or without alendronate sodium. PURPOSE: Randomized phase II trial to study the effectiveness of ketoconazole with or without alendronate sodium in treating patients who have metastatic prostate cancer.

NCT ID: NCT00005067 Terminated - Clinical trials for Adenocarcinoma of the Prostate

Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate Cancer

Start date: February 2000
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of photodynamic therapy with lutetium texaphyrin in treating patients with locally recurrent prostate cancer. Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This may be effective treatment for locally recurrent prostate cancer. Photosensitizing drugs, such as lutetium texaphyrin, are absorbed by cancer cells and, when exposed to light, become active and kill the cancer cells

NCT ID: NCT00005039 Terminated - Clinical trials for Adenocarcinoma of the Prostate

Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)

Start date: January 2000
Phase: Phase 2
Study type: Interventional

Randomized phase II trial to determine the effectiveness of vaccine therapy in treating patients who have advanced adenocarcinoma of the prostate (prostate cancer). Vaccines made from a person's prostate cancer cells may make the body build an immune response to kill tumor cells